Dynavax's Adjuvant-Based Bivalent COVID-19 Vaccine Candidate Shows Encouraging Preclinical Action

Comments
Loading...
  • Clover Biopharmaceuticals Ltd announced new promising data from a preclinical study on its bivalent vaccine candidate, which combines the trimeric spike antigens from the original SARS-CoV-2 strain and the omicron variant. 
  • Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus. It includes Dynavax Technologies Corporation's DVAX CpG 1018 advanced adjuvant and aluminum hydroxide. 
  • In a preclinical study, the bivalent vaccine candidate elicited broad neutralization against all Variants of Concern (VoC), including omicron, in primary vaccination and booster settings. 
  • Notably, compared to the monovalent omicron variant vaccine (SCB-2022B) alone, the bivalent COVID-19 vaccine demonstrated higher neutralization levels against most of the variants tested and comparable levels against omicron.
  • Clover expects to initiate a Phase 1 trial in Q2 evaluating SCB-2020S (a prototype and beta-variant chimeric vaccine candidate) to demonstrate proof-of-concept for variant strain change utilizing the Trimer-Tag platform. 
  • Price Action: DVAX shares are down 5.89% at $8.79 during the market session on the last check Thursday.
Overview Rating:
Speculative
50%
Technicals Analysis
100
0100
Financials Analysis
20
0100
Overview
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!